X4 Pharmaceuticals Stock Technical Analysis
| XFOR Stock | USD 3.41 0.04 1.19% |
As of the 15th of February 2026, X4 Pharmaceuticals owns the standard deviation of 4.56, and Market Risk Adjusted Performance of 0.0069. In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of X4 Pharmaceuticals, as well as the relationship between them. Please check out X4 Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if X4 Pharmaceuticals is priced more or less accurately, providing market reflects its prevailing price of 3.41 per share. Given that X4 Pharmaceuticals has jensen alpha of (0.09), we strongly advise you to confirm X4 Pharmaceuticals's latest market performance to make sure the company can sustain itself sooner or later.
X4 Pharmaceuticals Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as XFOR, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to XFORX4 Pharmaceuticals' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.X4 Pharmaceuticals Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 9.33 | Strong Buy | 5 | Odds |
Most XFOR analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand XFOR stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of X4 Pharmaceuticals, talking to its executives and customers, or listening to XFOR conference calls.
Can Biotechnology industry sustain growth momentum? Does XFOR have expansion opportunities? Factors like these will boost the valuation of X4 Pharmaceuticals. Anticipated expansion of XFOR directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating X4 Pharmaceuticals demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (8.92) | Revenue Per Share | Quarterly Revenue Growth 2.152 | Return On Assets | Return On Equity |
Investors evaluate X4 Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating X4 Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause X4 Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, X4 Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
X4 Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to X4 Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of X4 Pharmaceuticals.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in X4 Pharmaceuticals on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding X4 Pharmaceuticals or generate 0.0% return on investment in X4 Pharmaceuticals over 90 days. X4 Pharmaceuticals is related to or competes with Aligos Therapeutics, Karyopharm Therapeutics, Kezar Life, Senti Biosciences, INmune Bio, Skye Bioscience, and OnKure Therapeutics. X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and com... More
X4 Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure X4 Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess X4 Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.01 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 24.47 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 7.57 |
X4 Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for X4 Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as X4 Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use X4 Pharmaceuticals historical prices to predict the future X4 Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0092 | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0) |
X4 Pharmaceuticals February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0092 | |||
| Market Risk Adjusted Performance | 0.0069 | |||
| Mean Deviation | 3.12 | |||
| Semi Deviation | 3.78 | |||
| Downside Deviation | 4.01 | |||
| Coefficient Of Variation | 84181.05 | |||
| Standard Deviation | 4.56 | |||
| Variance | 20.82 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0) | |||
| Maximum Drawdown | 24.47 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 7.57 | |||
| Downside Variance | 16.12 | |||
| Semi Variance | 14.32 | |||
| Expected Short fall | (3.55) | |||
| Skewness | 0.9958 | |||
| Kurtosis | 3.79 |
X4 Pharmaceuticals Backtested Returns
X4 Pharmaceuticals retains Efficiency (Sharpe Ratio) of close to zero, which attests that the company had a close to zero % return per unit of price deviation over the last 3 months. X4 Pharmaceuticals exposes twenty-nine different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out X4 Pharmaceuticals' market risk adjusted performance of 0.0069, and Standard Deviation of 4.56 to validate the risk estimate we provide. The firm owns a Beta (Systematic Risk) of 1.47, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, X4 Pharmaceuticals will likely underperform. At this point, X4 Pharmaceuticals has a negative expected return of -0.0165%. Please make sure to check out X4 Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to decide if X4 Pharmaceuticals performance from the past will be repeated sooner or later.
Auto-correlation | -0.46 |
Modest reverse predictability
X4 Pharmaceuticals has modest reverse predictability. Overlapping area represents the amount of predictability between X4 Pharmaceuticals time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of X4 Pharmaceuticals price movement. The serial correlation of -0.46 indicates that about 46.0% of current X4 Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.46 | |
| Spearman Rank Test | -0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
X4 Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
X4 Pharmaceuticals Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for X4 Pharmaceuticals across different markets.
About X4 Pharmaceuticals Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of X4 Pharmaceuticals on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of X4 Pharmaceuticals based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on X4 Pharmaceuticals price pattern first instead of the macroeconomic environment surrounding X4 Pharmaceuticals. By analyzing X4 Pharmaceuticals's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of X4 Pharmaceuticals's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to X4 Pharmaceuticals specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2018 | 2025 (projected) | Payables Turnover | 0.19 | 0.11 | Days Of Inventory On Hand | 1.3K | 1.5K |
X4 Pharmaceuticals February 15, 2026 Technical Indicators
Most technical analysis of XFOR help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for XFOR from various momentum indicators to cycle indicators. When you analyze XFOR charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0092 | |||
| Market Risk Adjusted Performance | 0.0069 | |||
| Mean Deviation | 3.12 | |||
| Semi Deviation | 3.78 | |||
| Downside Deviation | 4.01 | |||
| Coefficient Of Variation | 84181.05 | |||
| Standard Deviation | 4.56 | |||
| Variance | 20.82 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | (0) | |||
| Maximum Drawdown | 24.47 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 7.57 | |||
| Downside Variance | 16.12 | |||
| Semi Variance | 14.32 | |||
| Expected Short fall | (3.55) | |||
| Skewness | 0.9958 | |||
| Kurtosis | 3.79 |
X4 Pharmaceuticals February 15, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as XFOR stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.04 | ||
| Daily Balance Of Power | 0.31 | ||
| Rate Of Daily Change | 1.01 | ||
| Day Median Price | 3.45 | ||
| Day Typical Price | 3.43 | ||
| Price Action Indicator | (0.01) | ||
| Market Facilitation Index | 0.13 |
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.